ArticleOpen forum infectious diseases2026
Comparative Effectiveness of Teicoplanin Versus Standard of Care Antibiotics for the Treatment of Gram-Positive Bacteremia: A Seven-Year Retrospective Analysis.
Article in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Glycopeptide antibiotics remain the cornerstone of therapy for serious Gram-positive bacteremia, yet comparative real-world effectiveness data between teicoplanin and standard-of-care agents remain limited in Middle Eastern healthcare settings. Objective: To compare clinical outcomes, safety profiles, and predictors of treatment failure between teicoplanin and standard-of-care antibiotics in adult patients with microbiologically confirmed Gram-positive bacteremia. Methods: We conducted a 7-year retrospective cohort study (January 2018-January 2025) at 2 tertiary care centers in Riyadh, Saudi Arabia. Adult patients receiving ≥72 hours of teicoplanin or standard-of-care antibiotics, including prespecified organism-directed beta-lactam therapy when clinically indicated, for Gram-positive bacteremia were included. Propensity score matching (1:1 ratio, caliper 0.2) was employed to balance baseline characteristics. Primary outcome was clinical cure at end of therapy. Secondary outcomes included 90-day all-cause mortality, nephrotoxicity, 14-day treatment failure, 30-day relapse, and antimicrobial switch due to toxicity. Results: Among 547 screened patients, 312 met inclusion criteria (teicoplanin n = 124; standard-of-care n = 188). Prematch analysis revealed significantly higher baseline illness severity in the teicoplanin cohort (median APACHE II 18 vs 14, Conclusions: Teicoplanin was associated with comparable clinical efficacy and lower nephrotoxicity compared with standard-of-care antibiotics. It may represent a reasonable alternative, particularly in patients at increased risk of renal adverse events. Prospective studies are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.